O'Mara Keliana, Weiss Michael D
Department of Pharmacy, University of Florida Health Shands Hospital, University of Florida, Gainesville, Florida.
Department of Pediatrics, University of Florida, Gainesville, Florida.
AJP Rep. 2018 Jul;8(3):e168-e173. doi: 10.1055/s-0038-1669938. Epub 2018 Sep 4.
Hypoxic-ischemic encephalopathy (HIE) is a significant cause of morbidity and mortality in neonates. Therapeutic hypothermia reduces the risk of death or disability. Providing optimal sedation while neonates are undergoing therapeutic hypothermia is likely beneficial but may present therapeutic challenges. There are limited data describing the use of dexmedetomidine for sedation in patients undergoing therapeutic hypothermia. The objective of this study is to evaluate the efficacy and short-term safety of dexmedetomidine infusion for sedation in term neonates undergoing therapeutic hypothermia for HIE.
缺氧缺血性脑病（HIE）是新生儿发病和死亡的重要原因。治疗性低温可降低死亡或残疾风险。在新生儿接受治疗性低温治疗时提供最佳镇静可能有益，但可能带来治疗挑战。关于右美托咪定在接受治疗性低温治疗的患者中用于镇静的相关数据有限。本研究的目的是评估右美托咪定输注用于足月新生儿HIE治疗性低温镇静的疗效和短期安全性。
